Literature DB >> 16824641

Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case-study.

Claudio Jommi1, Silvia Paruzzolo.   

Abstract

This article has two objectives. It firstly provides a general framework for variables that influence R&D (Research and Development) localisation by pharmaceutical and biotech companies. The analysis of R&D localization includes both in-house R&D and contracted R&D. Following a systematic literature search, these variables were classified into four distinct categories: regulatory environment, institutional framework, national systems of innovation and local development and specialisation. The authors highlight that some of these factors directly depend on the action of public administrations (e.g., patent protection, price regulation, public investments in research, and incentives to private companies); others are indirectly influenced by public policies (e.g., GDP growth rate, infrastructures). This theoretical framework was used to analyse the Italian case-study. Pros and cons of the Italian context were investigated from the point of view of multinational pharmaceutical companies and the Italian Association of Biotech Companies. Interviews were chosen as the most appropriate data gathering technique given the exploratory nature of the study of the Italian context. The paper is divided into five parts. A brief introduction provides figures showing that Europe has been loosing positions compared with other Continents and the same has occurred in Italy compared with other EU countries. The second one illustrates the methodology. The third one is focused on variables affecting R&D localisation. In the fourth section the Italian case-study is discussed. Theoretical and empirical findings are summarised and discussed in the conclusions.

Entities:  

Mesh:

Year:  2006        PMID: 16824641     DOI: 10.1016/j.healthpol.2006.05.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  4 in total

Review 1.  The last decade of Italian pharmaceutical policy: instability or consolidation?

Authors:  Giovanni Fattore; Claudio Jommi
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Current pipelines for neglected diseases.

Authors:  Paolo di Procolo; Claudio Jommi
Journal:  PLoS Negl Trop Dis       Date:  2014-09-04

3.  Did relaxing clinical trial regulation enhance the stock of scientific knowledge in India? Not necessarily.

Authors:  Bastian Rake; Carolin Haeussler
Journal:  PLoS One       Date:  2019-01-03       Impact factor: 3.240

4.  Ethics committees for clinical experimentation at international level with a focus on Italy.

Authors:  Zakira Naureen; Tommaso Beccari; Robert S Marks; Richard Brown; Lorenzo Lorusso; Derek Pheby; Stanislav Miertus; Karen L Herbst; Liborio Stuppia; Gary Henehan; Benedetto Falsini; Ludovica Lumer; Munis Dundar; Matteo Bertelli; International Bioethical Study Group
Journal:  Acta Biomed       Date:  2020-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.